Alfred Clinical Trials

Alfred Health has more than 700 open trials across 20 clinical disciplines, our clinical trial portfolio is one of the largest in the country.

Clear filter
604 clinical trials found
Clinical trials

HIGHLIFE

Expanded study of the HighLife™ 28mmtranscatheter trans-septal mitral valve in patients with moderatesevere or severe mitral regurgitation and at high surgical risk (NCT04029363)

Currently recruiting

ANZ NIHP

Extended (6-8 hours) Non-Ischemic Heart Preservation (NIHP) of Donor Hearts (ACTRN12620000595910)

Currently recruiting

POST-ETERNAL

Extending the time window for Tenecteplase by Effective RecanalizatioN of bAsilar artery occLusion in patients with POSTerior circulation stroke (NCT05105633)

Currently recruiting

ACTIVATE II

Feasibility Study of the Vessel Restoration System (VRS) for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery (SFA) and/or Proximal Popliteal Artery (PPA): ACTIVATE II (NCT05454995)

Recently completed/closed

FEISTY II

Fibrinogen Early in Severe Trauma StudY II (NCT05449834)

Currently recruiting

AMT-116

First-in-Human, Phase 1 Study of AMT-116, an Anti-CD44v9 Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors (NCT05725291)

Currently recruiting

AMT-253-01

First-in-Human, Phase 1 Study of AMT-253, an Anti-MUC18 Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors (NCT05906862)

Currently recruiting

2802-CL-0101

First-in-Human, Phase 1 Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of a Single-Induction Dose of convertibleCAR™-T Cells Armed with MicAbody™ Protein (ASP2802) Followed by Maintenance Booster Doses of the MicAbody Protein in Patients with CD20 Positive Refractory or Relapsed B-Cell Malignancies (Astellas) (NCT06248086)

Currently recruiting

FLASH

Fludrocortisone administration in aneurysmal subarachnoid haemorrhage (NCT06409364)

Coming soon

FRAIL-AS

Frailty response in patients with aortic stenosis undergoing transcatheter aortic valve implantation; a cluster randomised controlled trial (ACTRN12624000318583)

Currently recruiting

FRAIL-M

Frailty-stratified, randomised controlled Bayesian adaptive trial of bortezomib versus lenalidomide in transplant-ineligible myeloma (TI-NDMM) – the FRAIL-M study (ACTRN12619001199101)

Currently recruiting

FRONTIER-AP

FRONTIER-AP: Randomized controlled trial of endovascular versus standard medical therapy for stroke with medium sized vessel occlusion (ACTRN12621001746820)

Currently recruiting

B.E.A.S.T.

Full thickness Burn Wound Closure Using Bioengineered Skin: A Feasibility Study (ACTRN12623000349640)

Currently recruiting

FUNCTIAN

Functional Connectivity-informed Individualised Transcranial Magnetic Stimulation Therapy for Anorexia Nervosa (FUNCTIAN) – An Open-Label Proof of Concept Study (ACTRN12623001146684)

Currently recruiting

GENOPHENO

Genotype-Phenotype correlations in Multiple Sclerosis (MS) and Neuromyelitis Optica Spectrum Disorder (NMOSD) (Trial Not Registered)

Recently completed/closed

TRAILBLAZER-ALZ 5

Global Study to Investigate Safety and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease (NCT05508789)

Currently recruiting

GS-US-548-5916

GS-US-548-5916: A Phase 2 Study of Magrolimab Combination Therapy in Patients with Head and Neck Squamous Cell Carcinoma (NCT04854499)

No longer recruiting

HALEO

HALEO - A phase 3, multinational, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of NTLA-2002 in participants with hereditary angioedema [HAE] (NCT06634420)

Currently recruiting

Hearts and Minds

Hearts and Minds: A 3-arm Multicentre, Randomised, Double-Blind, Placebo-Controlled Study of Metformin and Atorvastatin for the Treatment of Depression and Medical Comorbidity (ACTRN12623000611628)

Currently recruiting

HELIOS-B

HELIOS-B: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy) (NCT04153149)

Currently recruiting
21 22 23 24 25